Benzinga | Oct 20, 2021 09:03AM EDT

Editas Medicine Says Clinical Data From Ongoing Phase 1/2 BRILLIANCE Clinical Trial Of EDIT-101 For LCA10 To Be Presented At European Society Of Gene And Cell Therapy Annual Congress

Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that an abstract featuring initial clinical data from the BRILLIANCE clinical trial of EDIT-101 has been selected for an oral presentation at the 2021 European Society of Gene and Cell Therapy (ESGCT) Annual Congress being held virtually October 19 -- 22, 2021. EDIT-101 is under development for the treatment of Leber congenital amaurosis 10 (LCA10), a CEP290-related retinal degenerative disorder.

"We are pleased to be working at the forefront of this research with Editas Medicine, evaluating genome editing for the treatment of CEP290-associated retinal disease in the BRILLIANCE trial," said Eric A. Pierce, M.D., Ph.D., Director of the Ocular Genomics Institute and William F. Chatlos Professor of Ophthalmology at Massachusetts Eye and Ear and Harvard Medical School, and the senior BRILLIANCE principal investigator. "I am highly encouraged by the early efficacy signals in the mid-dose cohort, which suggest positive biological activity and potential early clinical benefits. I am also very pleased that the initial data from the BRILLIANCE trial demonstrate a favorable safety profile. I believe that the trial data support continued EDIT-101 development as well as the evaluation of gene editing approaches for other inherited retinal disorders."

Details of the Editas Medicine presentation can be accessed on the ESGCT website.

Oral Presentation:

Title: BRILLIANCE: A Phase 1/2 single ascending dose study of EDIT-101, an in vivo CRISPR gene editing therapy, in CEP290-related retinal degeneration

Session Title: Parallel 4b: Gene editing II

Date and Time: Thursday, October 21, 2021, 10:15 -- 10:30 a.m. CET

Presenter: Dr. Eric A. Pierce, M.D., Ph.D., Director of the Inherited Retinal Disorders Service, Director of the Ocular Genomics Institute and William F. Chatlos Professor of Ophthalmology at Massachusetts Eye and Ear and Harvard Medical School, and a BRILLIANCE principal investigator.